ANIX · All filings · Read this filing

What changed 10-Q

Item 5. Other Information

2023-03-17 compared with 2022-09-09 · 4 added, 7 removed, 19 unchanged (37% of the section changed)

Other Information.

1 to Exclusive License Agreement between The Cleveland Clinic Foundation and Anixa Biosciences, Inc.

(Certain information has

been redacted in the marked portions of the exhibit.)

Certification

of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated September 9, 2022.

of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated March 17, 2023.

Certification

of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated September 9, 2022.

of Chief Executive Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated September 9, 2022.

of Chief Financial Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated September 9, 2022.

of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated March 17, 2023.

of Chief Executive Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated March 17, 2023.

of Chief Financial Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated March 17, 2023.

Inline XBRL Instance Document

15 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.